Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Brief Summary: This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received prior systemic therapy for advanced or metastatic RCC.


Options:
A: Arm Label: ccRCC molecular subgroup 1: 1A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: ccRCC molecular subgroup 1: 1B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 4: 4A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: ccRCC molecular subgroup 4: 4B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 2: 2C; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Sunitinib | Arm Label: ccRCC molecular subgroup 2: 2B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 3: 3B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 3: 3C; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Sunitinib | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): ccRCC molecular subgroup 1: 1A, ccRCC molecular subgroup 1: 1B, ccRCC molecular subgroup 2: 2B, ccRCC molecular subgroup 3: 3B, ccRCC molecular subgroup 4: 4A, ccRCC molecular subgroup 4: 4B | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): ccRCC molecular subgroup 1: 1B, ccRCC molecular subgroup 2: 2B, ccRCC molecular subgroup 3: 3B, ccRCC molecular subgroup 4: 4B | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): ccRCC molecular subgroup 2: 2C, ccRCC molecular subgroup 3: 3C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): ccRCC molecular subgroup 2: 2C, ccRCC molecular subgroup 3: 3C
B: Arm Label: Interleukin-2, interferon, bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: Interleukin-2 and interferon-alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interleukin-2, Drug: Interferon Alfa-2b | Intervention Type: DRUG; Name: Interleukin-2; Assigned to Arm(s): Interleukin-2 and interferon-alfa | Intervention Type: DRUG; Name: Interferon Alfa-2b; Assigned to Arm(s): Interleukin-2 and interferon-alfa | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Interleukin-2, interferon, bevacizumab
C: Arm Label: Atezolizumab and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab, Drug: Sunitinib | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib

Answer: D